DOAC Dipstick Testing Can Reliably Exclude the Presence of Clinically Relevant DOAC Concentrations in Circulation
Sandra Margetić
1
Department of Clinical Chemistry, Sestre Milosrdnice University Hospital Center, Zagreb County, Croatia
,
Ivana Ćelap
1
Department of Clinical Chemistry, Sestre Milosrdnice University Hospital Center, Zagreb County, Croatia
,
Arijana Lovrenčić Huzjan
2
Department of Neurology, Sestre Milosrdnice University Hospital Center, Zagreb County, Croatia
,
Marijana Bosnar Puretić
2
Department of Neurology, Sestre Milosrdnice University Hospital Center, Zagreb County, Croatia
,
Sandra Šupraha Goreta
3
Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb, Croatia
,
Anesa Čajević Glojnarić
1
Department of Clinical Chemistry, Sestre Milosrdnice University Hospital Center, Zagreb County, Croatia
,
Diana Delić Brkljačić
4
Department of Cardiovascular Diseases, Sestre Milosrdnice University Hospital Center, Zagreb County, Croatia
,
Pavao Mioč
4
Department of Cardiovascular Diseases, Sestre Milosrdnice University Hospital Center, Zagreb County, Croatia
,
Job Harenberg
5
DOASENSE GmbH, Heidelberg, Germany
6
University of Heidelberg, Heidelberg, Baden-Württemberg, Germany
,
Svetlana Hetjens
7
Department of Medical Statistics and Biomathematics, University of Heidelberg Medical Faculty Mannheim, Heidelberg, Germany
,
Christel Weiss
7
Department of Medical Statistics and Biomathematics, University of Heidelberg Medical Faculty Mannheim, Heidelberg, Germany
› Author AffiliationsFunding The study was part of the research project entitled “New oral anticoagulants: relationship between drug concentration and anticoagulant effect” (IP-2016–06–8208), which was funded by the Croatian Scientific Foundation.
In certain clinical situations, it is necessary to determine whether clinically relevant plasma levels of direct oral anticoagulants (DOACs) are present. We examined whether qualitative testing of DOACs in urine samples can exclude DOAC plasma concentrations of ≥30 ng/mL. This prospective single-center cohort study included consecutive patients treated with an oral direct factor Xa inhibitor (DXI) (apixaban, n = 31, rivaroxaban, n = 53) and direct thrombin inhibitor (DTI) (dabigatran, n = 44). We aimed to define the negative predictive value (NPV) and other statistical parameters of detecting DXIs and DTIs by DOAC Dipstick at plasma concentrations of ≥30 ng/mL. We also determined the best-fit threshold plasma levels using chromogenic substrate assays by logistic regression analysis. Between July 2020 and July 2021, 128 eligible patients (mean age 66 years, 55 females) were included into the study. The NPVs and sensitivities for DXI and DTI of DOAC Dipstick were 100% at ≥30 ng/mL plasma, for specificities 6 and 21% and for positive predictive values 62 and 72%, respectively. All diagnostic statistical tests improved to values between 86 and 100% at best-fitting plasma thresholds of ≥14 ng/mL for DXI and ≥19 ng/mL for DTI. Visual analysis using the DOAC Dipstick was 100% in agreement with that of the optoelectronic DOASENSE Reader for all the three DOACs.
DOAC Dipstick testing can reliably exclude the presence of DOACs in urine samples at best-fitting thresholds of >14 and >19 ng/mL in plasma. The performance of the DOAC Dipstick at detecting lower DOAC concentrations in plasma requires confirmation.
Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
References
1
Schünemann HJ,
Cushman M,
Burnett AE.
et al.
American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Adv 2018; 2 (22) 3198-3225
4
Ten Cate H,
Henskens YM,
Lancé MD.
Practical guidance on the use of laboratory testing in the management of bleeding in patients receiving direct oral anticoagulants. Vasc Health Risk Manag 2017; 13: 457-467
5
Favaloro EJ,
Pasalic L,
Curnow J,
Lippi G.
Laboratory monitoring or measurement of direct oral anticoagulants (DOACs): advantages, limitations and future challenges. Curr Drug Metab 2017; 18 (07) 598-608
6
Gosselin RC,
Adcock DM,
Bates SM.
et al.
International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of direct oral anticoagulants. Thromb Haemost 2018; 118 (03) 437-450
7
Antovic JP,
Skeppholm M,
Eintrei J.
et al.
Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma. Eur J Clin Pharmacol 2013; 69 (11) 1875-1881
9
Schreiner R,
Hetjens S,
Giese C.
et al.
Determination of rivaroxban, apixaban, edoxaban and dabigatran by liquid chromatography-tandem mass-spectrometry and chromogenic assays from urine samples of patients. Res Pract Thromb Haemost 2017; 1: PB491
10
Schmohl M,
Gansser D,
Moschetti V,
Stangier J.
Measurement of dabigatran plasma concentrations by calibrated thrombin clotting time in comparison to LC-MS/MS in human volunteers on dialysis. Thromb Res 2015; 135 (03) 532-536
13
Harenberg J,
Du S,
Krämer S,
Weiss C,
Krämer R,
Wehling M.
Patients' serum and urine as easily accessible samples for the measurement of non-vitamin K antagonist oral anticoagulants. Semin Thromb Hemost 2015; 41 (02) 228-236
15
Levy JH,
Ageno W,
Chan NC,
Crowther M,
Verhamme P,
Weitz JI.
Subcommittee on Control of Anticoagulation.
When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost 2016; 14 (03) 623-627
16
Gosselin RC,
Francart SJ,
Hawes EM,
Moll S,
Dager WE,
Adcock DM.
Heparin-calibrated chromogenic anti-Xa activity measurements in patients receiving rivaroxaban: can this test be used to quantify drug level?. Ann Pharmacother 2015; 49 (07) 777-783
17
Ćelap I,
Margetić S,
Brčić M,
Mihić R.
Analytical verification and comparison of chromogenic assays for dabigatran, rivaroxaban and apixaban determination on BCSXP and STA Compact Max analysers. Biochem Med (Zagreb) 2020; 30 (01) 010706
18
DeLong ER,
DeLong DM,
Clarke-Pearson DL.
Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44 (03) 837-845
19
Du S,
Weiss C,
Christina G.
et al.
Determination of dabigatran in plasma, serum, and urine samples: comparison of six methods. Clin Chem Lab Med 2015; 53 (08) 1237-1247
20
Harenberg J,
Du S,
Wehling M.
et al.
Measurement of dabigatran, rivaroxaban and apixaban in samples of plasma, serum and urine, under real life conditions. An international study. Clin Chem Lab Med 2016; 54 (02) 275-283
21
Harenberg J,
Beyer-Westendorf J,
Crowther M.
et al;
Working Group Members.
Accuracy of a rapid diagnostic test for the presence of direct oral factor Xa or thrombin inhibitors in urine-a multicenter trial. Thromb Haemost 2020; 120 (01) 132-140
23
Douxfils J,
Adcock DM,
Bates SM.
et al.
2021 update of the International Council for Standardization in Haematology recommendations for laboratory measurement of direct oral anticoagulants. Thromb Haemost 2021; 121 (08) 1008-1020
25
Douketis JD,
Spyropoulos AC,
Duncan J.
et al.
Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant. JAMA Intern Med 2019; 179 (11) 1469-1478